Surgery Websites
Willenbring Lab »  Alumni »  Postdoctoral Fellows »  Aras N. Mattis, M.D., Ph.D.
Aras N. Mattis, M.D., Ph.D.

Aras N. Mattis, M.D., Ph.D.

Assistant Professor, UCSF Department of Pathology

Open Popup

University of California, Berkeley, B.A., Molecular and Cell Biology, 1998

University of Illinois, Chicago, M.D., Medicine, 2007

University of Illinois, Urbana-Champaign, Ph.D., Biochemistry, 2007

University of California, San Francisco, Anatomic Pathology Resident 2007-2009

University of California, San Francisco, Fellow, Surgical Pathology, 2009-2010

University of California, San Francisco, Fellow, Liver/GI Pathology, 2010-Present

  • American Board of Pathology, Anatomic Pathology
  • UCSF Department of Pathology
  • California Institute for Regenerative Medicine
  • Liver and Gastrointestinal Pathology
  • Development and metabolism, liver and gastrointestinal tumors, site-specific recombination.
  • Hepatocytes for transplant and disease modeling, micro-RNA regulation of hepatocyte
  • Liver diseases including metabolic, pediatric, fibrotic, idiopathic, stem cell derived

Aras N. Mattis, M.D., Ph.D., is a board-certified anatomic pathologist and clinical fellow in the Willenbring Lab. Dr. Mattis trained at the University of Illinois at Urbana-Champaign, earning both his doctorates, Biochemistry and Medicine, there in 2007. He continued his clinical training in Pathology at the University of California San Francisco completing residency in Anatomic Pathology with subsequent fellowship training in Surgical Pathology and Liver and gastrointestinal pathology under his clinical mentor, Dr. Linda Ferrell. Since 2010, he has worked in the Willenbring Lab, investigating the basic mechanisms of liver development and disease in the with a specific focus on liver metabolism and fatty liver disease as well as micro-RNA regulation of liver metabolism.

Dr. Mattis' postdoctoral work includes the use of translational human biopsy material as well as patient-derived induced pluripotent stem cell reprogramming to hepatocytes. As a long-term goal, this work aims to develop a humanized liver mouse model of fatty liver disease. Aras is supported by the UCSF CIRM clinical fellow training grant and continues to work closely with the UCSF Department of Pathology as a clinical researcher.

Data provided by UCSF Profiles, powered by CTSI
  • Genetic Regulation of Nonalcoholic Fatty Liver Disease
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jun 2021
    -
    Mar 2025
    Co-Principal Investigator
  • Regulation of Lipid Metabolism by miR-29a within Hepatocytes
    Sponsor:
    Sponsor ID:
    Funding Period:
    Sep 2013
    -
    Jul 2018
    Principal Investigator
MOST RECENT PUBLICATIONS FROM A TOTAL OF 37
Data provided by UCSF Profiles, powered by CTSI
  1. Mohammed N, Rabinovitch PS, Wang D, Kovári BP, Mattis AN, Lauwers GY, Choi WT. Nonampullary Duodenal Adenomas in Familial Adenomatous Polyposis and Sporadic Patients Lack the DNA Content Abnormality That is Characteristic of the Adenoma-Carcinoma Sequence Involved in the Development of Other Gastrointestinal Malignancies. Am J Surg Pathol. 2021 Jun 17. View in PubMed
  2. Bowman CJ, Zhang R, Balitzer D, Wang D, Rabinovitch PS, Kovári BP, Mattis AN, Kakar S, Lauwers GY, Choi WT. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue. Mod Pathol. 2021 Oct; 34(10):1889-1900. View in PubMed
  3. Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT. Gastric Intestinal Metaplasia in Mucosa Adjacent to Gastric Cancers Is Rarely Associated With the Aneuploidy That Is Characteristic of Gastric Dysplasia or Cancer. Am J Surg Pathol. 2021 10 01; 45(10):1374-1381. View in PubMed
  4. Peaslee C, Esteva-Font C, Su T, Munoz-Howell A, Duwaerts CC, Liu Z, Rao S, Liu K, Medina M, Sneddon JB, Maher JJ, Mattis AN. Doxycycline Significantly Enhances Induction of Induced Pluripotent Stem Cells to Endoderm by Enhancing Survival Through Protein Kinase B Phosphorylation. Hepatology. 2021 Oct; 74(4):2102-2117. View in PubMed
  5. Duwaerts CC, Le Guillou D, Her CL, Phillips NJ, Willenbring H, Mattis AN, Maher JJ. Induced Pluripotent Stem Cell-derived Hepatocytes From Patients With Nonalcoholic Fatty Liver Disease Display a Disease-specific Gene Expression Profile. Gastroenterology. 2021 Jun; 160(7):2591-2594.e6. View in PubMed
  6. View All Publications

 

Site Directory
    X